Testing combinations of biologic drugs for rheumatoid and psoriatic arthritis
Tests whether combining biologic drugs helps adults with rheumatoid or psoriatic arthritis.
Key facts
- Who runs it
- Cardiff University
- Where
- Badalona and Barcelona, SpainSee the 2 sites
- Trial code
- EU 2024-518011-19-01
- ISRCTN50666516
- Registry title
- Testing the safety and efficacy of combining biologic drugs in Rheumatoid and Psoriatic Arthritis
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 10 people, planned
- Started
- 1 Sept 2025
- Planned end
- 1 Nov 2026
- Type of study
- Interventional
- Record updated
- 14 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rheumatoid arthritis or psoriatic arthritis who still have active arthritis while taking a TNF inhibitor drug.
- Age
- 18 years or older, no upper age limit
- Sex
- All sexes can join
- Disease stage
- Active arthritis: DAS28 score above 3.2 for rheumatoid arthritis, or DAPSA above 14 for psoriatic arthritis
- Earlier treatment
- Current treatment with an approved TNF inhibitor for at least 6 weeks. Previous treatment with IL-6 inhibitors (tocilizumab or sarilumab) is not allowed.
Main reasons for not taking part
- Known HIV or hepatitis B/C infection
- Active infection or contraindication to the biologic drugs
- Cancer within the last 10 years (basal cell carcinoma excepted)
- Pregnant or breast-feeding women
- Presence of a transplanted organ (corneal transplant more than 3 months before screening excepted)
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Adult patients (≥18 years old), no upper age limit
- Patient must fulfil either European Alliance of Associations for Rheumatology (EULAR)/Albumin: Creatinine Ratio (ACR) classification criteria for the diagnosis of Rheumatoid Arthritis, or Classification Criteria of Psoriatic Arthritis (CASPAR)
- Current treatment with any approved Tumour Necrosis Factor inhibitors (TNFis) for at least 6 weeks
- Active arthritis as defined by: • DAS28 score > 3.2 for Rheumatoid Arthritis • Disease Activity in Psoriatic Arthritis (DAPSA) >14 for Psoriatic Arthritis
- Signed informed consent
Who cannot take part
- Known HIV or hepatitis B/C infection (satisfactory hepatitis B screening test must have been done previously)
- Any other contra-indication to the study medications as detailed in their summaries of product characteristics (SmPC), including low IgG levels at clinician’s discretion
- Receipt of live vaccine <4 weeks prior to first infusion
- Major surgery in 3 months prior to first infusion
- Presence of a transplanted organ (with the exception of a corneal transplant >3 months prior to screening)
- Known recent substance abuse (drug or alcohol)
- Previous treatment with any IL-6is (tocilizumab or sarilumab)
- Intra articular or parenteral corticosteroids ≤ 4 weeks prior Visit 2
- Oral prednisolone more than 10mg per day or equivalent ≤ 4 weeks prior to Visit 2
- Contraindications to any of the biologic treatment e.g. active infection
- Malignancy (other than basal cell carcinoma) within the last 10 years
- New York Heart Association (NYHA) grade 3 or 4 congestive cardiac failure
- Demyelinating disease
- History of or current primary inflammatory joint disease or primary autoimmune disease other than RA
- Active infection
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
- Sepsis of a prosthetic joint within 12 months or indefinitely if the joint remains in situ
- Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period
- Patients currently recruited to other clinical trial(s) involving an Investigational Medicinal Pproduct (IMP), except any observational follow-up periods not involving an IMP)
- Women who are pregnant or breast-feeding
- Women of child-bearing potential, or males whose partners are women of child-bearing potential, unwilling to use effective contraception during the study and for at least 3 months after stopping study treatment
- Septic arthritis within a native joint within the last 12 months
Where in Spain
- Hospital Germans Trias i PujolBadalona, SpainNot yet recruiting
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
About the trial
What the trial wants to find out
Proportion of patients who achieve disease remission at week 24 will be the primary endpoint. Remission will be defined by: • Clinical Disease Activity Index (CDAI) 2.8 or < 2.8 in RA • DAPSA <4 in PsA
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMIDS) USING SYSTEMS APPROACHES
- Plain-language title
- Testing combinations of biologic drugs for rheumatoid and psoriatic arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 14 July 2026